Printer Friendly

Sonic Media Corporation Completes Acquisition of Global Botanics Inc., Including Patents for Natural Treatment of Herpes & Other Viral Infections.

Business Editors

VANCOUVER, B.C.--(BUSINESS WIRE)--March 25, 2004

Sonic Media Corporation (OTCBB:SMED: "Sonic") today announced the acquisition of Global Botanics, Inc. (GBI), a company that has patented processes involving the use of a natural plant extract to treat genital herpes and other viral infections. Genital herpes alone afflicts one out of four women and one out of five men in North America, representing some 55 million individuals.

GBI, now a wholly owned Sonic subsidiary, is the exclusive supplier of a resin extract called Virastatin(TM) that is derived from Larrea Tridentata, a desert shrub indigenous to the southwestern U.S. and northern Mexico. Virastatin is the only patented, natural product on the market targeting herpes anti-viral treatment, and the only Larrea-based product that is readily absorbed into the digestive tract for maximum results.

Under a share exchange with GBI's two main shareholders, Sonic acquired GBI's four U.S. patents, the resin extraction production rights, and worldwide licensing and marketing privileges to Virastatin. Revenues are expected from the sale of Virastatin to multiple licensees, royalties on products sold by licensees, and potential licensing of the extract for use in over-the-counter pharmaceutical products and possible development of ethical drugs.

Virastatin has undergone 18 years of research and development, including nearly eight years of informal consumer testing during which more than 3,500 users heard about preliminary products based on the substance through word of mouth. Open, multicenter studies of oral and topical Virastatin conducted in 1996 indicate an overall 97.8% success rate in healing genital herpes and shingles lesions in patients whose immune systems are not compromised.

In addition, no adverse effects were reported from sponsored in vitro and in vivo animal studies, the open clinical studies, or from consumer use reports.

The first six commercially available products based on Virastatin were introduced late last year by LarreaRx, Inc., a non-exclusive licensee. The products include dietary supplements, cold sore lotions and penetrating sprays sold under the Virox and Shegoi brand names. Virox products are currently distributed through Tree of Life, United Natural Foods Incorporated and Select Nutrition in the U.S. and London Drugs, GNC, Overwaitea, Whole Foods and Thrifty in Canada. Shegoi products are marketed through direct marketing channels.

The four GBI patents (U.S. patents 5,837,252; 5,945,106; 6,004,559; and 6,039,955) cover methods of extracting the Larrea Tridentata resin as well as the use of the extracts for treating human herpes viruses, symptomatic herpes lesions and inflammatory disease conditions. All four patents were issued between 1998 and 2000.

The patent claims related to herpes treatment encompass cold sores (herpes simplex 1), genital herpes (herpes simplex 2), shingles (herpes simplex 3), Epstein-Barr virus/chronic fatigue syndrome (human herpes virus 4), cytomegalovirus (human herpes virus 5), roseoloviruses (human herpes viruses 6 and 7), and Kaposi's sarcoma (herpes virus 8).

GBI is pursuing pending patent applications in the U.S. and other Patent Cooperation Treaty countries/territories, such as Australia, EU and Japan, which expand on the patented technologies.

About Sonic Media Corporation

Sonic Media Corp is engaged in the industrial field of applied biosciences research and development. The company also participates in the retail sector with worldwide distribution of nutriceutical and cosmiceutical products. The company currently obtains its revenues from a number of products containing a patented ingredient that is derived from the oldest living plant on earth, Larrea Tridentata. These products, currently protected by four United States patents with additional U.S. and international patents pending, have demonstrated results in treating herpes virus conditions; inflammatory conditions, including arthritis, sinusitis, gastrointestinal disorders, psoriasis; and various microbial and fungal conditions. The company plans to become the world leader in the industrialization and commercialization of Larrea for a wide range of health and consumer products. The company is currently undergoing a name change to better represent its core business.

Forward-Looking Statement

Any statements contained herein that are not historical facts are forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Potential factors could cause actual results to differ materially from those expressed or implied by such statements. Information on the potential factors that could affect the Company's actual results of operations is included in its filings with the Securities and Exchange Commission. These risks may be further discussed in periodic reports and registration statements to be filed by the Company from time to time with the Securities and Exchange Commission in the future.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Mar 25, 2004
Words:751
Previous Article:PCT Media Group Publishes Quality Assurance & Food Safety Magazine.
Next Article:Macrovision's ''Hacker University'' at E3 to Preview World's Most Robust Copy Protection Technology for Gaming Industry.


Related Articles
Herpes latency makes 'anti-sense.'
Hardy viruses survive drug assault.
Herpes gets in your eyes.
Herpes virus homes in on cancer target.
Suppressive drug therapy hinders herpes. (Biomedicine).
Selected guidelines (*). (Featured CME Topic: Female Patient).
Viral encephalitis in England, 1989-1998: what did we miss? (Research).
Connection blocker may stop viruses.
One-two punch vaccine fights herpes with antibodies, T cells.
Disseminated neonatal herpes caused by herpes simplex virus types 1 and 2.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters